ZIOPHARM, Inc. Presents Promising Preclinical Pediatric Sarcoma Data with Oral and IV Palifosfamide at the 2011 CTOS/MSTS Meeting

Published: Oct 28, 2011

NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide (Zymafos™ or ZIO-201) in a pediatric sarcoma model. The data was detailed in an oral session of the 2011 meeting of the combined Connective Tissue Oncology Society (CTOS) Musculoskeletal Tumor Society (MSTS), being held October 26 – 29, 2011 in Chicago, IL.

Back to news